Multiple studies have shown that high expression levels of HOXA-AS2 were significantly related to a poor prognosis in patients with gastric cancer 39, breast cancer 40, papillary thyroid cancer 44, non-small lung cancer 46, colorectal cancer 53, and hepatocellular carcinoma 51. This evidence concerns the gene HOXA-AS2 and breast cancer.